(E)-3-{3-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-phenyl}-pent-2-en-1-ol | 174258-43-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (E)-3-{3-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-phenyl}-pent-2-en-1-ol
• 英文别名: (E)-3-[3-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]phenyl]pent-2-en-1-ol
• CAS: 174258-43-6
• 化学式: C₂₃H₂₂F₃NO₃
• 分子量: 417.428
• InChiKey: VNWFUKDJYZKABA-LFIBNONCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  55.5
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (E)-3-{3-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-phenyl}-pent-2-en-1-ol 在 三苯基膦 、 三氟乙酸 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 9.5h， 生成 (E)-2-(3-{3-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-phenyl}-pent-2-enyl)-[1,2,4]oxadiazolidine-3,5-dione
  参考文献：
  名称：

  New Azolidinediones as Inhibitors of Protein Tyrosine Phosphatase 1B with Antihyperglycemic Properties

  摘要：

  Insulin resistance in the liver and peripheral tissues together with a pancreatic cell defect are the common causes of type 2 diabetes. It is now appreciated that insulin resistance can result from a defect in the insulin receptor signaling system, at a site post binding of insulin to its receptor. Protein tyrosine phosphatases (PTPases) have been shown to be negative regulators of the insulin receptor. Inhibiton of PTPase may be an effective method in the treatment of type 2 diabetes. A series of azolidinediones has been prepared as protein tyrosine phosphatase 1B (PTP1B) inhibitors. Several compounds were potent inhibitors against the recombinant rat and human PTP1B enzymes with submicromolar IC50 values. Elongated spacers between the azolidinedione moiety and the central aromatic portion of the molecule as well as hydrophobic groups at the vicinity of this aromatic region were very important to the inhibitory activity. Oxadiazolidinediones 87 and 88 and the corresponding acetic acid analogues 119 and 120 were the best h-PTP1B inhibitors with IC50 values in the range of 0.12-0.3 mu M. Several compounds normalized plasma glucose and insulin levels in the ob/ob and db/db diabetic mouse models.

  DOI：

  10.1021/jm990476x
• 作为产物：
  描述：

  4-(氯甲基)-5-甲基-2-[4-(三氟甲基)苯基]-1,3-噁唑 在 jones reagent 、 sodium hydride 、 二异丁基氢化铝 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙醚 、 N,N-二甲基甲酰胺 、 丙酮 、 甲苯 为溶剂， 反应 53.5h， 生成 (E)-3-{3-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-phenyl}-pent-2-en-1-ol
  参考文献：
  名称：

  New Azolidinediones as Inhibitors of Protein Tyrosine Phosphatase 1B with Antihyperglycemic Properties

  摘要：

  Insulin resistance in the liver and peripheral tissues together with a pancreatic cell defect are the common causes of type 2 diabetes. It is now appreciated that insulin resistance can result from a defect in the insulin receptor signaling system, at a site post binding of insulin to its receptor. Protein tyrosine phosphatases (PTPases) have been shown to be negative regulators of the insulin receptor. Inhibiton of PTPase may be an effective method in the treatment of type 2 diabetes. A series of azolidinediones has been prepared as protein tyrosine phosphatase 1B (PTP1B) inhibitors. Several compounds were potent inhibitors against the recombinant rat and human PTP1B enzymes with submicromolar IC50 values. Elongated spacers between the azolidinedione moiety and the central aromatic portion of the molecule as well as hydrophobic groups at the vicinity of this aromatic region were very important to the inhibitory activity. Oxadiazolidinediones 87 and 88 and the corresponding acetic acid analogues 119 and 120 were the best h-PTP1B inhibitors with IC50 values in the range of 0.12-0.3 mu M. Several compounds normalized plasma glucose and insulin levels in the ob/ob and db/db diabetic mouse models.

  DOI：

  10.1021/jm990476x

文献信息

• Azolidinediones as antihyperglycemic agents
  申请人：American Home Products Corporation

  公开号：US05468762A1

  公开（公告）日：1995-11-21

  This invention relates to compounds which have oral antihyperglycemic activity of the formula: ##STR1## wherein: R.sup.1 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.8 cycloalkyl, thienyl, furyl, pyridyl, ##STR2## R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl; X os O or S; n is 0, 1, or 2; A is ##STR3## Y is O or S; Z is N or CH when Y is O and Z is CH when Y is S; or a pharmaceutically acceptable salt thereof.

  这项发明涉及具有口服抗高血糖活性的化合物，其化学式为：##STR1## 其中：R.sup.1为C.sub.1 -C.sub.6烷基，C.sub.3 -C.sub.8环烷基，噻吩基，呋喃基，吡啶基，##STR2## R.sup.2为氢或C.sub.1 -C.sub.6烷基；X为O或S；n为0、1或2；A为##STR3## Y为O或S；Z为N或CH，当Y为O时Z为CH，当Y为S时Z为CH；或其药用盐。
• New azolidinediones and thiadiazolidinediones as antihyperglycemic agents
  申请人：American Home Products Corporation

  公开号：US05532256A1

  公开（公告）日：1996-07-02

  This invention relates to novel compounds which have demonstrated oral antihyperglycemic activity in diabetic ob/ob and db/db mice, animal models on non-insulin dependent diabetes mellitus (NIDDM ot Type II diabetes). These compounds have the formula: ##STR1## wherein: R.sup.1 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.8 cycloalkyl, thienyl, furyl, pyridyl, ##STR2## where R.sup.10 is hydrogen, C.sub.1 -C.sub.6 alkyl, fluorine, chlorine, bromine, iodine, C.sub.1 -C.sub.6 alkyoxy, trifluoroalkyl or trifluoroalkoxy; R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl; X is O or S; n is 0, 1, or 2; A is ##STR3## where R.sup.3 is hydrogen, C.sub.1 -C.sub.6 alkyl, halogen, C.sub.1 -C.sub.6 alkoxy, trifluoroalkyl or trifluoroalkoxy; B is ##STR4## where R.sup.4 is hydrogen, C.sub.1 -C.sub.6 alkyl, allyl, C.sub.6 -C.sub.10 aryl, C.sub.6 -C.sub.10 aryl-(CH.sub.2).sub.1-6 --, fluorine, chlorine, bromine, iodine, trimethylsilyl or C.sub.3 -C.sub.8 cycloalkyl; R.sup.5 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.6 -C.sub.10 aryl, or C.sub.6 -C.sub.10 aryl-(CH.sub.2).sub.1-6 --; m is 0, 1, or 2; R.sup.6 is hydrogen or C.sub.1 -C.sub.6 alkyl; R.sup.7 is hydrogen or C.sub.1 -C.sub.6 alkyl; R.sup.8 and R.sup.9 are selected independently from hydrogen, C.sub.1 -C.sub.6 alkyl, fluorine, chlorine, bromine, or iodine; Y is S; Z is N or CH; or a pharmaceutically acceptable salt thereof.

  这项发明涉及一种新型化合物，已在糖尿病ob/ob和db/db小鼠中表现出口服抗高血糖活性，这些小鼠是非胰岛素依赖型糖尿病（NIDDM或2型糖尿病）的动物模型。这些化合物的分子式为：其中：R.sup.1为C.sub.1 -C.sub.6烷基，C.sub.3 -C.sub.8环烷基，噻吩基，呋喃基，吡啶基，其中R.sup.10为氢，C.sub.1 -C.sub.6烷基，氟，氯，溴，碘，C.sub.1 -C.sub.6烷氧基，三氟甲基或三氟甲氧基；R.sup.2为氢或C.sub.1 -C.sub.6烷基；X为O或S；n为0, 1或2；A为其中R.sup.3为氢，C.sub.1 -C.sub.6烷基，卤素，C.sub.1 -C.sub.6烷氧基，三氟甲基或三氟甲氧基；B为其中R.sup.4为氢，C.sub.1 -C.sub.6烷基，烯丙基，C.sub.6 -C.sub.10芳基，C.sub.6 -C.sub.10芳基-(CH.sub.2).sub.1-6 --，氟，氯，溴，碘，三甲基硅基或C.sub.3 -C.sub.8环烷基；R.sup.5为氢，C.sub.1 -C.sub.6烷基，C.sub.6 -C.sub.10芳基，或C.sub.6 -C.sub.10芳基-(CH.sub.2).sub.1-6 --；m为0, 1或2；R.sup.6为氢或C.sub.1 -C.sub.6烷基；R.sup.7为氢或C.sub.1 -C.sub.6烷基；R.sup.8和R.sup.9分别选自氢，C.sub.1 -C.sub.6烷基，氟，氯，溴，或碘；Y为S；Z为N或CH；或其药学上可接受的盐。
• NEW AZOLIDINEDIONES AS ANTIHYPERGLYCEMIC AGENTS
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP0759919A1

  公开（公告）日：1997-03-05
• AZOLIDINEDIONES AS ANTIHYPERGLYCEMIC AGENTS
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP0759919B1

  公开（公告）日：1998-11-11
• US5468762A
  申请人：——

  公开号：US5468762A

  公开（公告）日：1995-11-21